Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using \[18F\]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.

Key facts

Study ID

NCT00547612

Run by

National Institutes of Health Clinical Center (CC)

People needed

33

Starts

2007-09-01

Expected to finish

2008-12-01

Last updated by the study team

2012-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG performance status 0-2
• WBC ≥ 1,200/mm³
• Creatinine < 2.0 mg/dL
• Negative pregnancy test
• Fertile patients must agree to use effective contraception
• Not pregnant or nursing

You may not qualify if…

• Allergy to IV contrast
• Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan
• PRIOR CONCURRENT THERAPY:
• Inclusion criteria:
• More than 4 weeks since prior abdominal surgery
• Exclusion criteria:
• Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits
• Aprepitant within 72 hours of [18F]-labeled substance P antagonist receptor quantifier positron emission tomography

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.